Gilead Sciences flips its 2026 outlook, signaling a shift from a projected profit to a loss. The company now expects an adjusted loss of $1.05 to $0.65 per share, a stark reversal from the earlier guidance of $8.45 to $8.85 per share. This change follows mounting expenses tied to recent acquisitions.

The hit comes largely from an $11.5 billion in acquired in-process research‑and‑development charges, which analysts say will erode adjusted earnings by roughly $9.50 per share. These costs stem from recent deals aimed at bolstering Gilead’s pipeline, yet they have tightened the company’s financial footing in the short term.

The reversal will likely pressure Gilead’s stock, already trading near $1.64 down, as investors reassess the company’s ability to generate returns amid high R&D outlays. Market watchers will monitor how the firm balances future growth initiatives against the immediate impact of these acquisition costs.

Gilead’s decision reflects a broader trend in the biopharma sector, where firms absorb hefty integration expenses to secure innovative assets. While the loss signals short‑term weakness, it also underscores the company’s commitment to expanding its therapeutic portfolio, a strategy that could pay dividends once the acquired projects reach commercialization.